Skip to main content
. Author manuscript; available in PMC: 2014 May 13.
Published in final edited form as: Cancer Cell. 2013 May 13;23(5):693–704. doi: 10.1016/j.ccr.2013.03.025

Figure 5. Efficacy of PARP inhibitor on cancer-associated BRCA1 and BARD1 mutants.

Figure 5

(A) The effect of PJ34 on the recruitment of the P1749R and M1775R mutants of BRCA1 to DNA damage sites. GFP-BRCA1 mutants were expressed in U2OS cells with or without the treatment of PJ34. The relocation of BRCA1 mutants to DNA damage sites was monitored in a time course following laser microirradiation. (B) The effect of PJ34 on the recruitment of the C645R and V695L mutants of BARD1 to DNA damage sites. GFP-BARD1 mutants were expressed in U2OS cells with or without the treatment of PJ34. The relocation of BARD1 mutants to DNA damage sites was monitored in a time course following laser microirradiation. Scale bar = 10 µm. (C) The sensitivities of cells bearing cancer-associated BRCA1 or BARD1 mutants to low dose of IR in the presence or absence of PJ34. (D) The effect of different doses of PJ34 on the cells bearing the P1749R mutant treated by IR. The error bars represent the standard deviation.